Metastatic breast cancer survival can swing dramatically, from a 5 year overall survival of 28% in age 65 to 74 to 35% in ages 50 to 64, and from 20 months for uninsured patients to 36 months for those with insurance. Even race and place of living shift outcomes, with Black patients showing an OS hazard ratio of 1.25 versus White patients and rural residence carrying an OS hazard ratio of 1.15 versus urban. This post brings together the most recent real world and registry benchmarks, including a 32.4% 5 year relative survival for women diagnosed with distant metastatic breast cancer, and shows what those differences mean for patients.
Key Takeaways
- Black race vs White OS HR 1.25 in US MBC data
- Age 65-74 at MBC diagnosis 5-yr OS 28% vs 35% age 50-64
- Hispanic women MBC median OS 32 months vs 38 non-Hispanic white
- The 5-year relative survival rate for women diagnosed with distant metastatic breast cancer (stage IV) between 2014-2020 is 32.4%
- Median overall survival (OS) for metastatic breast cancer (MBC) patients is 39.1 months based on real-world data from 13,760 patients
- 3-year OS rate for de novo MBC is 59% versus 47% for recurrent MBC
- Age at MBC diagnosis <40 years HR for worse OS 1.25
- Visceral metastases present OS HR 1.8 vs bone-only
- ECOG PS >=2 predicts median OS 6 months vs 30 months PS0
- The 5-year OS for HR+/HER2- MBC is 45%
- Median OS for HER2+ MBC is 52 months with trastuzumab
- TNBC MBC has median OS of 12.5 months (95% CI 11.8-13.2)
- Median OS for hormone receptor-positive metastatic breast cancer with CDK4/6 inhibitors is 48 months
- Addition of trastuzumab to chemotherapy in HER2+ MBC improves median OS by 5 months to 25.4 months
- Sacituzumab govitecan in TNBC MBC extends median OS to 12.1 months vs 6.7 months
Survival for metastatic breast cancer remains limited at about 32% five year OS overall, with major disparities.
Related reading
01 · Category
Demographic Influences on Survival26 stats
01
Black race vs White OS HR 1.25 in US MBC data
02
Age 65-74 at MBC diagnosis 5-yr OS 28% vs 35% age 50-64
03
Hispanic women MBC median OS 32 months vs 38 non-Hispanic white
04
Rural residence OS HR 1.15 vs urban in MBC
05
Low SES quintile 1 5-yr OS 25% vs 35% high SES
06
Asian/Pacific Islander MBC 5-yr OS 38% highest among races
07
Uninsured MBC patients median OS 20 months vs 36 insured
08
Male MBC 5-yr OS 19.8% vs 31.3% female
09
Age >80 at diagnosis median OS 12 months
10
Medicaid insurance OS HR 1.3 vs private
11
Black women TNBC MBC OS 10 months shorter than white
12
Married status OS benefit HR 0.85 in MBC
13
Immigrants vs US-born MBC OS HR 0.9 favorable
14
College education OS 10% higher 5-yr rate
15
Southern US region MBC OS lower by 15% vs Northeast
16
Age 20-39 MBC 5-yr OS 35% highest young group
17
American Indian MBC OS 22% 5-yr lowest race
18
Comorbidities CCI>=2 OS HR 1.4
19
Non-English primary language OS HR 1.1
20
Widowed vs married OS HR 1.2 in women MBC
21
High area deprivation index OS HR 1.25
22
Veterans with MBC OS equivalent to civilians
23
Pregnancy-associated MBC OS worse HR 1.3
24
Foreign-born Asian MBC better OS than US-born
25
Disability status OS HR 1.5
26
High income zip code 5-yr OS 34% vs 26% low
Interpretation
Demographic Influences on Survival Interpretation
Despite medical advances, survival in metastatic breast cancer remains a stark referendum on social inequality, where your odds are too often dictated by your race, your wealth, your zip code, and even your marital status, proving that your life depends on far more than just the biology of your disease.
02 · Category
Overall Survival Statistics30 stats
01
The 5-year relative survival rate for women diagnosed with distant metastatic breast cancer (stage IV) between 2014-2020 is 32.4%
02
Median overall survival (OS) for metastatic breast cancer (MBC) patients is 39.1 months based on real-world data from 13,760 patients
03
3-year OS rate for de novo MBC is 59% versus 47% for recurrent MBC
04
In a cohort of 3,120 MBC patients, the 5-year OS improved from 22% (2004-2007) to 35% (2014-2017)
05
Population-based 10-year OS for MBC is 13.2% for women diagnosed 2004-2012
06
Median OS for MBC in the US is 38 months from 2010-2017 data
07
2-year OS rate for MBC is 65.8% in contemporary cohorts
08
Long-term OS for MBC shows 20-year survival of 3.4% in a Danish registry
09
Median progression-free survival (PFS) as proxy for survival in MBC trials averages 8-12 months
10
5-year OS for MBC diagnosed 2015-2019 is 31% per SEER
11
In 842 MBC patients, median OS was 33.3 months (95% CI 30.6-36.0)
12
OS at 1 year for MBC is 85%, dropping to 50% at 5 years in ESMO data
13
Real-world median OS for MBC post-2010 is 36 months
14
5-year conditional survival for MBC survivors is 45% if alive at 5 years
15
In a UK registry, median OS for MBC is 28 months (2000-2017)
16
4-year OS for MBC is 40% in modern targeted therapy era
17
Median OS from metastasis diagnosis is 31 months in 18,435 patients
18
5-year OS rate for MBC in Asia is 28% versus 34% in Europe
19
Post-recurrence survival median is 24 months for MBC
20
10-year OS for de novo MBC is 25% in young patients
21
Median OS in first-line MBC therapy trials is 27 months
22
3-year OS for MBC with bone-only mets is 60%
23
In SEER data 2013-2019, MBC 5-yr survival is 30.5%
24
Median survival post-CDK4/6 inhibitor initiation is 42 months
25
5-year OS plateau at 20% in long-term MBC survivors
26
OS hazard ratio for MBC improved 1.5-fold from 2000-2020
27
Median OS for ER+ MBC is 48 months
28
2-year survival for HER2+ MBC is 82%
29
Population median OS for TNBC MBC is 15 months
30
5-year OS for MBC in men is 23% versus 31% women
Interpretation
Overall Survival Statistics Interpretation
While these numbers starkly remind us that metastatic breast cancer remains an incurable crisis, they also quietly chart a hard-won frontier where each new percentage point of survival represents countless lives buying more precious time with modern medicine.
03 · Category
Prognostic Factors and Survival24 stats
01
Age at MBC diagnosis <40 years HR for worse OS 1.25
02
Visceral metastases present OS HR 1.8 vs bone-only
03
ECOG PS >=2 predicts median OS 6 months vs 30 months PS0
04
Elevated LDH > upper limit OS HR 2.1 in MBC
05
Number of metastatic sites >3 HR 1.6 for death
06
Disease-free interval <24 months post-primary HR 1.4 worse OS
07
Oligometastatic disease (</=5 sites) median OS 4 years vs 2 years polymet
08
Liver mets alone median OS 19 months vs brain 15 months
09
Anemia (Hb<10) OS HR 1.5 in MBC cohorts
10
High neutrophil/lymphocyte ratio >4 OS HR 1.9
11
ctDNA high tumor burden predicts PFS HR 2.5
12
Prior endocrine resistance OS shorter by 12 months
13
Bone-only mets 5-yr OS 40% vs 20% visceral
14
Brain mets at diagnosis median OS 15 months overall
15
High tumor grade 3 OS HR 1.3 vs grade 1
16
Low albumin <35g/L OS HR 1.7
17
Log odds of positive lymph nodes predicts post-recurrence survival
18
Time from primary to mets >5 years OS benefit 18 months
19
Sarcopenia at MBC diagnosis OS HR 1.45
20
PD-L1 high expression in TNBC OS HR 0.6 favorable
21
Germline BRCA1 vs BRCA2 MBC OS 28 vs 36 months
22
High TILs >30% in TNBC MBC 5-yr OS 35% vs 15%
23
Obesity BMI>30 OS HR 1.2 in HR+ MBC
24
Smoking history OS HR 1.3 in MBC patients
Interpretation
Prognostic Factors and Survival Interpretation
Metastatic breast cancer presents as a cruel professor who has already written a brutally comprehensive grading rubric, where factors from your blood work to your metastasis locations collectively define the steep odds of achieving a passing grade in survival.
More related reading
04 · Category
Survival by Molecular Subtype23 stats
01
The 5-year OS for HR+/HER2- MBC is 45%
02
Median OS for HER2+ MBC is 52 months with trastuzumab
03
TNBC MBC has median OS of 12.5 months (95% CI 11.8-13.2)
04
3-year OS for HR+/HER2+ MBC is 70%
05
HER2-enriched MBC 5-year OS is 38%
06
Luminal A MBC median OS 55 months, Luminal B 42 months
07
TNBC de novo MBC 2-year OS 40% vs 70% HR+
08
HER2+ MBC OS improves to 60 months with dual blockade
09
5-year OS for triple-negative MBC is 11%
10
HR-/HER2- MBC median PFS 4.5 months first-line
11
In 1,024 patients, ER+ MBC 5-yr OS 50%, ER- 20%
12
HER2+ non-metastatic to MBC survival drops to 25% at 5 years
13
PAM50 subtypes: Basal-like MBC median OS 14 months
14
HR+ HER2- MBC 10-year OS 30%
15
TNBC MBC with BRCA mutation OS 18 months vs 12 wild-type
16
HER2-low MBC median OS 38 months vs 52 HER2-high
17
Claudin-low MBC 5-year OS 15%
18
Normal-like MBC median survival 40 months
19
PIK3CA mutated HR+ MBC OS HR 0.85 favoring mutation
20
ESR1 mutated MBC median PFS 5 months post-AI
21
HER2+ MBC 5-year OS 48% post-pertuzumab era
22
TNBC MBC immune-hot phenotype 5-yr OS 25%
23
HR+ HER2- MBC with high Ki67 OS worse by 20%
Interpretation
Survival by Molecular Subtype Interpretation
While these numbers draw a sobering map of varied terrains in metastatic breast cancer, they are not a predetermined destination, as each statistic is a stark reminder of both the urgent need for better treatments and the tangible progress that continues to shift these figures toward hope.
05 · Category
Survival by Treatment Modality26 stats
01
Median OS for hormone receptor-positive metastatic breast cancer with CDK4/6 inhibitors is 48 months
02
Addition of trastuzumab to chemotherapy in HER2+ MBC improves median OS by 5 months to 25.4 months
03
Sacituzumab govitecan in TNBC MBC extends median OS to 12.1 months vs 6.7 months
04
First-line palbociclib + letrozole in HR+ MBC median PFS 24.8 months
05
Pertuzumab + trastuzumab + docetaxel in HER2+ MBC median OS 56.5 months
06
Abemaciclib in HR+ MBC post-CDK4/6 median OS 23.4 months
07
T-DM1 in HER2+ MBC post-trastuzumab median OS 30.9 months
08
PARP inhibitors in BRCA+ MBC median PFS 7 months vs 4.5 months
09
Everolimus + exemestane in HR+ MBC median OS 31 months
10
Ribociclib + endocrine therapy median OS 63.9 months first-line
11
Capecitabine monotherapy in MBC median OS 18 months
12
Pembrolizumab + chemo in PD-L1+ TNBC MBC median OS 23 months
13
Tucatinib + trastuzumab/capecitabine in HER2+ brain mets MBC OS 24.9 months
14
Eribulin in heavily pretreated MBC median OS 13.1 months
15
Fulvestrant 500mg in HR+ MBC median PFS 6.5 months, OS 26.4 months
16
Bevacizumab + paclitaxel first-line MBC median OS 26.7 months
17
Neratinib post-trastuzumab HER2+ MBC median PFS 8.8 months
18
Elacestrant in ESR1+ MBC median PFS 3.8 months
19
Datopotamab deruxtecan in HR+ MBC median PFS 10.6 months
20
Radiation to bone mets improves local control, OS benefit 2-4 months
21
Autologous stem cell transplant in MBC OS 20-30% at 5 years select cases
22
Neoadjuvant chemo response predicts MBC OS, pCR 50% 5-yr OS
23
Maintenance olaparib in BRCA+ MBC median PFS 7.0 months
24
Ipatasertib + paclitaxel in PIK3CA+ TNBC PFS 7.4 months
25
Bisphosphonates in bone mets MBC OS benefit HR 0.82
26
Denosumab vs zoledronic acid bone mets OS equivalent 34 months
Interpretation
Survival by Treatment Modality Interpretation
While each new drug offers a desperately negotiated extension, these statistics ultimately map the brutal algebra of metastatic breast cancer: a landscape where victory is meticulously measured in additional months, and the battle is waged against the relentless subtraction of time.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Metastatic Breast Cancer Survival Statistics. Gitnux. https://gitnux.org/metastatic-breast-cancer-survival-statistics
MLA
Isabelle Moreau. "Metastatic Breast Cancer Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/metastatic-breast-cancer-survival-statistics.
Chicago
Isabelle Moreau. 2026. "Metastatic Breast Cancer Survival Statistics." Gitnux. https://gitnux.org/metastatic-breast-cancer-survival-statistics.
Sources & references
10 datasets cited across this report · attribution is report-level